NASDAQ: NBSENeubase Therapeutics Inc Stock
$0.43+0.00 (+0%)
Updated Apr 19, 2024
NBSE Price
$0.43
Fair Value Price
N/A
Market Cap
$1.60M
52 Week Low
$0.39
52 Week High
$4.80
P/E
-0.06x
P/B
0.18x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$13.73M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.04
Operating Cash Flow
-$15M
Beta
0.87
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NBSE Overview
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NBSE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NBSE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NBSE is good value based on its book value relative to its share price (0.18x), compared to the US Biotechnology industry average (5.74x)
P/B vs Industry Valuation
NBSE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NBSE due diligence checks available for Premium users.
Be the first to know about important NBSE news, forecast changes, insider trades & much more!
NBSE News
Valuation
NBSE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.06x
Industry
15.81x
Market
40.51x
NBSE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.18x
Industry
5.74x
NBSE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NBSE's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.8M
Profit Margin
0%
NBSE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$18.6M
Liabilities
$9.5M
Debt to equity
1.04
NBSE's short-term assets ($13.35M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NBSE's short-term assets ($13.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NBSE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NBSE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
$0.0
Financing
-$174.5k
NBSE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NBSE vs Biotech Stocks
Neubase Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.